This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in substance use disorder (SUD) treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

This Joint SAMHSA-CMS informational Bulletin provides guidance to states and school systems about addressing mental health and substance use issues in schools. It provides examples of approaches for services in schools and describes some Medicaid authorities that states may use to cover services.

This guide offers best practices for treating women living with substance use disorders in co-ed treatment and recovery settings. It highlights the importance of gender differences, cultural sensitivity, and developing healthy relationships.

This guide reviews screening tools for alcohol use and interventions for pregnant women and women of childbearing age to prevent fetal alcohol spectrum disorders (FASD). It also outlines methods for identifying people living with FASD and modifying treatment accordingly. Access the literature review.

This guide enhances the counselor’s treatment manual in the Matrix series, addressing the specific needs of women who misuse stimulants. It contains materials to help counselors conduct intensive outpatient treatment sessions on relationships, trauma, body image, and family roles.

This toolkit outlines the essential components for supportive housing services and programs for people living with mental illness disorders. It discusses how to develop and integrate evidence-based programs in mental health systems. The toolkit includes eight booklets on program development.

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.